- Home
- DBD vs SUPN Comparison
DBD vs SUPN Comparison
Compare DBD & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DBD | SUPN |
|---|---|---|
| Founded | 1859 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.0B |
| IPO Year | 2023 | 2010 |
Fundamental Metrics
Financial Performance| Metric | DBD | SUPN |
|---|---|---|
| Price | $70.57 | $49.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $90.00 | $61.60 |
| AVG Volume (30 Days) | 301.8K | ★ 643.6K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 677.27 | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $3,805,700,000.00 | $392,755,000.00 |
| Revenue This Year | $3.56 | $22.70 |
| Revenue Next Year | $3.25 | $19.14 |
| P/E Ratio | $511.79 | ★ N/A |
| Revenue Growth | ★ 1.46 | N/A |
| 52 Week Low | $47.34 | $31.16 |
| 52 Week High | $89.05 | $59.68 |
Technical Indicators
Market Signals| Indicator | DBD | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 28.88 | 46.10 |
| Support Level | $68.51 | $47.73 |
| Resistance Level | $70.84 | $52.36 |
| Average True Range (ATR) | 3.05 | 2.17 |
| MACD | -1.26 | 0.11 |
| Stochastic Oscillator | 0.00 | 39.57 |
Price Performance
Historical ComparisonAbout DBD Diebold Nixdorf Incorporated
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.